^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    pirotinib (KBP-5209)

    i
    Other names: KBP-5209, KBP5209
    Associations

    News

    Trials
    Company:
    Sihuan Pharmaceutical
    Drug class:
    EGFR inhibitor, HER2 inhibitor, HER4 inhibitor
    Related drugs:
    Associations

    News

    Trials
    11ms
    PYTHON: Preoperative Treatment of HR+/HER2+Breast Cancer With Pirotinib, Trastuzumab and AI Research (clinicaltrials.gov)
    P2, N=48, Recruiting, Tianjin Medical University Cancer Institute and Hospital
    New P2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive
    |
    Herceptin (trastuzumab) • pirotinib (KBP-5209)
    4years
    [VIRTUAL] Studies on the efficacy of pyrotinib in the treatment of HER-2 positive advanced solid tumors. (ASCO 2020)
    11 cases of trastuzumab were changed to anti-HER-2 after treatment failure, of which 2 cases were treated with pirotinib after trastuzumab and lapatinib failed treatment...The common symptoms were diarrhea (100%), hand and foot skin reaction (38%), rash (8%), etc. Grade 3 to 4 adverse events occurred in 1 patient (8%) received pyrotinib plus capecitabine...The treatment of HER-2 positive advanced solid tumors with pyrotinib have good exact affect, and the toxicity could be controlled. Research Funding: None
    Clinical
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive • HER-2 overexpression • HER-2 amplification
    |
    Herceptin (trastuzumab) • lapatinib • capecitabine • Irene (pyrotinib) • pirotinib (KBP-5209)